Evaluating ferric citrate for treating high phosphate levels in children with kidney disease

A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease

This study is testing if ferric citrate can safely help children with kidney disease lower their high phosphate levels.

Quick facts

• Phase: PHASE3
• Study type: Interventional
• Enrollment: 45 (estimated)
• Ages: 6 Years to 16 Years
• Sex: All
• Sponsor: Keryx Biopharmaceuticals (industry)
• Locations: 14 sites (Birmingham, Alabama and 13 other locations)
• Trial ID: NCT04523727 on ClinicalTrials.gov

What this trial studies

This study evaluates the safety and tolerability of ferric citrate in children aged 6 to 17 years who have hyperphosphatemia related to chronic kidney disease (CKD). Participants will either be on chronic dialysis or have a significantly reduced kidney function. The study aims to determine how well ferric citrate can manage phosphate levels in this pediatric population. The trial will involve monitoring participants for any adverse effects and assessing the overall effectiveness of the treatment.

Who should consider this trial

Good fit: Ideal candidates are children aged 6 to 17 years with CKD requiring dialysis or with severely reduced kidney function and a history of hyperphosphatemia.

Not a fit: Patients who do not have hyperphosphatemia or whose kidney function is not severely impaired may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could help manage phosphate levels in children with CKD, improving their overall health and quality of life.

How similar studies have performed: Other studies have explored treatments for hyperphosphatemia in CKD, but the specific use of ferric citrate in this pediatric population is relatively novel.

Eligibility criteria

Inclusion Criteria:

* Age 6 years to \<17 years at Screening.
* Weight ≥ 20 kilograms (kg) (dry weight for dialysis participants) at Screening.
* Chronic kidney disease (CKD) requiring chronic dialysis (i.e., hemodialysis or peritoneal dialysis), or CKD not on dialysis with an estimated glomerular filtration rate (eGFR) \<30 milliliters per minute (mL/min)/1.73 meters squared (m\^2) at Screening.
* Documented history of CKD-related hyperphosphatemia for at least 3 months prior to the screening visit.
* If participant is or is not on phosphate binder(s) at Visit 1, serum phosphorus must be:

  * 6 to \<13 years: \>5.8 milligrams per deciliter (mg/dL).
  * 13 to \<17 years: \>4.5 mg/dL.
* If participant is on phosphate binder(s) at Visit 1, and serum phosphorus is not greater than the above stated age-limit criteria, approximately 1 to 4-weeks of washout period is required and at Visit 1a or Visit 1b, serum phosphorus must be greater than the age above stated age-limit criteria.
* Transferrin saturation (TSAT) \<50%.
* Serum ferritin of \<650 nanograms per milliliter (ng/mL).
* Parent/legal guardian must be willing and able to give written informed consent, and child (participant) willing and able to give age-appropriate assent according to local regulatory requirements.
* Female participants of childbearing potential, defined as post menarche and not surgically sterile, must have a negative serum pregnancy test.
* Dialysis adequacy stable on current mode of dialysis prior to screening and agree to maintain dialysis prescription for the duration of the pharmacodynamic assessment period unless changes are needed for safety. A minimum dialysis adequacy (dialysis clearance of urea-dialysis time/volume of distribution of urea \[Kt/V\]), defined by the following:

  1. Hemodialysis adequacy: single-pool Kt/V ≥1.2 for at least 1 hemodialysis session within 2 months.
  2. Peritoneal dialysis: At least 1Kt/V reading ≥1.8 within 4 months.

Exclusion Criteria:

* Active significant GI disorder, including overt GI bleeding or active inflammatory bowel disease.
* Liver transaminases (aspartate aminotransferase \[AST\] or alanine aminotransferase \[ALT\]) \>3× the upper limit of normal at Screening.
* Unable to swallow pills, if participant requires tube feeding, ferric citrate must be taken orally and not administered via feeding tube.
* Non-renal cause of hyperphosphatemia.
* Active drug or alcohol dependence or abuse (excluding tobacco use or medicinal marijuana) within the 12 months prior to Screening or evidence of such abuse (in the opinion of the Investigator).
* Malignancy, except for participants who have been disease-free for at least 2 years after curative therapy.
* Participants with a functioning organ transplant.
* A known allergy or intolerance to ferric citrate or any of its constituents.
* Female participants who do not agree to remain abstinent or assent to use a combination of 2 of the following highly effective birth control methods for at least 28 days before the first dose, during the study (including during dose interruptions), and for at least 30 days after the last dose:

  * Barrier method of contraception: condoms (female or male) with or without a spermicidal agent, diaphragm, or cervical cap with spermicide.
  * Intrauterine device (IUD).
  * Hormone-based contraceptives which are associated with inhibition of ovulation.
* Females who are pregnant or breast-feeding other children. Participants who are being breastfed are eligible to participate in this study.
* Any other medical condition that, in the opinion of the Investigator, renders the participant unable to or unlikely to complete the trial or that would interfere with optimal participation in the trial or produce significant risk to the participant.
* The participant, in the opinion of the Investigator, is unable to adhere to the requirements of the study.
* Receipt of any investigational drug within 4 weeks before Screening.
* History of hemochromatosis or iron overload syndrome (e.g, hereditary sideroblastic anemia, thalassemia).

Where this trial is running

Birmingham, Alabama and 13 other locations

• University of Alabama at Birmingham (UAB) - Children's of Alabama — Birmingham, Alabama, United States (RECRUITING)
• Phoenix Childrens Hospital — Phoenix, Arizona, United States (RECRUITING)
• University of California, San Francisco (UCSF) - Department of Nephrology — San Francisco, California, United States (RECRUITING)
• Stanford University Medical Center — Stanford, California, United States (RECRUITING)
• Children's Hospital Colorado — Aurora, Colorado, United States (RECRUITING)
• University of South Florida — Tampa, Florida, United States (RECRUITING)
• Johns Hopkins Hospital — Baltimore, Maryland, United States (RECRUITING)
• Helen DeVos Children's Hospital at Spectrum Health — Grand Rapids, Michigan, United States (RECRUITING)
• University of Minnesota — Minneapolis, Minnesota, United States (RECRUITING)
• Children's Mercy Hospital - Kansas City — Kansas City, Missouri, United States (RECRUITING)
• University of New Mexico — Albuquerque, New Mexico, United States (RECRUITING)
• Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio, United States (RECRUITING)
• University of Utah — Salt Lake City, Utah, United States (RECRUITING)
• Seattle Children's Hospital — Seattle, Washington, United States (RECRUITING)

Study contacts

• Study coordinator: Akebia Medical Information

Conditions: Hyperphosphatemia Related to Chronic Kidney Disease, hyperphosphatemia, chronic kidney disease, CKD, ferric citrate, pediatric, dialysis